Literature DB >> 10492184

Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.

S J Jacobsen1, D J Jacobson, C J Girman, R O Roberts, T Rhodes, H A Guess, M M Lieber.   

Abstract

PURPOSE: We describe treatments for benign prostatic hyperplasia (BPH) among men participating in the Olmsted County study of urinary symptoms and health status among men during 10,000 person-years of followup.
MATERIALS AND METHODS: A cohort of 2,115 men 40 to 79 years old was randomly selected from an enumeration of the Olmsted County, Minnesota population (55% response rate). Participants completed a previously validated baseline questionnaire to assess symptom severity and voided into a portable urometer. A 25% random subsample underwent transrectal sonographic imaging of the prostate to determine prostate volume and measurement of serum prostate specific antigen. Followup included retrospective review of community medical records and completion of a biennial questionnaire to determine the occurrence of medical and surgical treatment for BPH in the subsequent 6 years.
RESULTS: During more than 10,000 person-years of followup 167 men were treated, yielding an overall incidence of 16.0/1,000 person-years. There was a strong age related increase in risk of any treatment from 3.3/1,000 person-years for men 40 to 49 years old to more than 30/1,000 person-years for those 70 years old or older. Men with moderate to severe symptoms (American Urological Association symptom index greater than 7), depressed peak urinary flow rates (less than 12 ml. per second), enlarged prostate (greater than 30 ml.) or elevated serum prostate specific antigen (1.4 ng./ml. or greater) had about 4 times the risk of BPH treatment than those who did not. After adjustment for all measures simultaneously an enlarged prostate (hazard ratio 2.3, 95% confidence interval [CI] 1.1, 4.7), depressed peak flow rate (hazard ratio 2.7, 95% CI 1.4, 5.3) and moderate to severe symptoms (hazard ratio 5.3, 95% CI 2.5, 11.1) at baseline each independently predicted subsequent treatment.
CONCLUSIONS: While repeat contact and availability of urological measurements during the study period may have influenced treatment decisions in this cohort, the data demonstrate that treatment is common in elderly men with nearly 1 in 4 receiving treatment in the eighth decade of life. Furthermore, these data suggest that men with moderate to severe lower urinary tract symptoms, impaired flow rates or enlarged prostates are more likely to undergo treatment, with increases in risk of similar magnitude to those associated with adverse outcomes, such as acute urinary retention.

Entities:  

Mesh:

Year:  1999        PMID: 10492184

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  [Urological illnesses in the elderly].

Authors:  J M Wolff
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

2.  Healthcare practices among blacks and whites with urinary tract symptoms.

Authors:  Daniel L Howard; Bennett G Edwards; Kimberly Whitehead; M Ahinee Amamoo; Paul A Godley
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

3.  Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation.

Authors:  Adam S Bellinger; Sean P Elliott; Liu Yang; John T Wei; Christopher S Saigal; Alexandria Smith; Timothy J Wilt; Seth A Strope
Journal:  J Urol       Date:  2012-03-15       Impact factor: 7.450

4.  Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.

Authors:  Thomas Rhodes; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Cynthia J Girman; Michael M Lieber; George G Klee; Kitaw Demissie; Steven J Jacobsen
Journal:  Urology       Date:  2012-03       Impact factor: 2.649

5.  Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.

Authors:  Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; George G Klee; Cynthia J Girman; Michael M Lieber
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

6.  Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men.

Authors:  Aruna V Sarma; Jennifer L St Sauver; John M Hollingsworth; Debra J Jacobson; Michaela E McGree; Rodney L Dunn; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2011-11-23       Impact factor: 2.649

Review 7.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

8.  Changing patients' profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspective.

Authors:  Mohamed A Elkoushy; Ahmed M Elshal; Mostafa M Elhilali
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 9.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

10.  Intravesical prostatic protrusion in men in Olmsted County, Minnesota.

Authors:  Michael M Lieber; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Cynthia J Girman; Steven J Jacobsen
Journal:  J Urol       Date:  2009-10-17       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.